A link between hypercholesterolemia and chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 57, Issue 4, 2016, Pages 797-802

  Chow, Signy ^a,b   Buckstein, Rena ^a,b   Spaner, David E ^a,b,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

cholesterol; Chronic lymphocytic leukemia; HMG CoA reductase inhibitor; inflammation; lipoprotein; signal transduction; statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CHOLESTEROL BLOOD LEVEL; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; DRUG USE; FEMALE; GENE DELETION; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; BLOOD; COHORT ANALYSIS; COMPLICATION; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME;

AGED; BIOMARKERS; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INCIDENCE; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 84961055416     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1088651     Document Type: Article

References (24)

1. Agnoli C, Grioni S, Sieri S, et al. Colorectal cancer risk and dyslipidemia: A case-cohort study nested in an Italian multicentre cohort. Cancer Epidemiol 2014; 38: 144-151.
2. Mucci LA, Stampfer MJ. Mounting evidence for prediagnostic use of statins in reducing risk of lethal prostate cancer. J Clin Oncol 2014; 32: 1-2.
3. Kitahara CM, Berrington de González A, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 2011; 29: 1592-1598.
4. Nelson ER, Wardell SE, Jasper JS, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 2013; 342: 1094-1098.
5. Masoodi M, Lee E, Eiden M, et al. A role for oleoylethanolamide in chronic lymphocytic leukemia. Leukemia 2014; 28: 1381-1387.
6. Tung S, Shi Y, Wong K, et al. PPARα and fatty acid oxidation mediate glucocorticoid resistance in CLL. Blood 2013; 122: 969-980.
7. Spaner DE, Lee E, Shi Y, et al. PPAR-Alpha is a therapeutic target for chronic lymphocytic leukemia. Leukemia 2013; 27: 1090-1099.
8. Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer: A systematic review and meta-Analysis. Ann Oncol 2013; 24: 1721-1730.
9. Kaye JA, Meier CR, Walker AM, et al. Statin use, hyperlipidaemia, and the risk of breast cancer. Br J Cancer 2002; 86: 1436-1439.
10. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367: 1792-1802.
11. Nowakowski GS, Maurer MJ, Habermann TM, et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010; 28: 412-417.
12. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of CLL: A report from the International Workshop on CLL updating the NCI-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
13. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
14. Spaner DE. Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia. Leukemia 2012; 26: 1144-1145.
15. Tung S, Spaner DE. A role for Danazol in CLL. Leukemia 2012; 26: 1684-1686.
16. Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population: A cross-sectional study. Arch Intern Med 2012; 172: 1707-1710.
17. Anderson T, Grégoire J, Hegele R, et al. 2012 update of the Canadian Cardiovascular Society guidelines for diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol 2013; 29: 151-167.
18. Tomic J, Lichty B, Spaner DE. Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood 2011; 117: 2668-2680.
19. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121: 2111-2117.
20. Fessler MB, Parks JS. Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling. J Immunol 2011; 187: 1529-1535.
21. York AG, Bensinger SJ. Subverting sterols: rerouting an oxysterol-signaling pathway to promote tumor growth. J Exp Med 2013; 210: 1653-1656.
22. Shanafelt TD, Rabe KG, Kay NE, et al. Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leuk Lymphoma 2010; 51: 1233-1240.
23. Friedman DR, Magura LA, Warren HA, et al. Statin use and need for therapy in chronic lymphocytic leukemia. Leuk Lymphoma 2010; 51: 2295-2298.
24. Catovsky D, Wade R, Else M. The clinical significance of patients' sex in chronic lymphocytic leukemia. Haematologica 2014; 99: 1088-1094.